Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort.

Emilie ChalayerAlexis TalbotLaurent FrenzelLionel KarlinPhilippe ColletDenis GuyotatMichel AttalXavier LeleuBernard Tardy

Published in: Journal of thrombosis and haemostasis : JTH (2022)

Prospective studies are warranted in light of these results to improve VTE risk stratification and to design adapted thromboprophylaxis in terms of timing and dose.

Keyphrases

venous thromboembolism
multiple myeloma
direct oral anticoagulants
low dose
high dose
case control
cell therapy
newly diagnosed
mesenchymal stem cells
atrial fibrillation